BioSpace News Archive

Repare Therapeutics Inc. announced the first patient has been dosed in the Company’s Phase 1 LIONS clinical trial evaluating RP-1664, a potential first-in-class, highly selective, oral polo-like kinase 4 inhibitor, for the monotherapy treatment of adult and adolescent patients enriched for TRIM37-high solid tumors.

Ironwood Pharmaceuticals, Inc., a GI-focused healthcare company, reported its fourth quarter and full year 2023 results and recent business performance.

Palatin Technologies, Inc. announced financial results for its fiscal second quarter ended December 31, 2023.

Selkirk Pharma, Inc. announced the Aseptic Process Simulation qualification of its sterile manufacturing facility and newly available fill/finish capacity.

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.

The New England Journal of Medicine published results from a positive Phase 2 clinical trial demonstrating frexalimab significantly slowed disease activity in people with relapsing multiple sclerosis, corresponding to 89% and 79% reduction in new gadolinium-enhancing T1 brain lesions at Week 12 in the high- and low-dose treatment arms compared to placebo, meeting the study’s primary endpoint.

Indaptus Therapeutics, Inc., a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced that Jeffrey A. Meckler, Chief Executive Officer, and Nir Sassi, Chief Financial Officer, will present a corporate update at the 2024 BIO CEO & Investor Conference.

Fate Therapeutics, Inc. announced that the Company will host a conference call and live audio webcast on Monday, February 26, 2024 at 5:00 PM ET to report its fourth quarter and full year 2023 financial results and provide a corporate update.

Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market for bid price and publicly held shares.

FreezeM, an Agri-tech pioneering biotechnology company that offers Breeding-as-a-Service for Black Soldier Fly protein factories, announced the closure of $14.2 million in Series A funding.